Menlo Park, CA-based company Intersect ENT has raised $30 million in Series D financing led by Norwest Venture Partners. The company is working to develop treatments for ear, nose and throat ailments associated with chronic sinusitis. Proceeds of the round will reportedly be used “for commercial expansion of the company’s Propel mini-sinus transplants and to fund clinical studies of its latest product, an office-based treatment for chronic sinusitis sufferers.” Intersect ENT also has a steroidal treatment for inflammation in the works. Also participating in the recent financing were return investors Kleiner Perkins, U.S. Venture Partners, PTV Sciences and Medtronic.
